Radius Health

Radius Health is an American biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS, an anabolic agent for the treatment of postmenopausal women with osteoporosis. Radius Health was founded in 2003 and is headquartered in Waltham, Massachusetts.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Radius Health balance sheet

Report period2016 2017 2018 2019 2020 2021
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Radius Health cash flows

Report period2016 2017 2018 2019 2020 2021
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Adjusted EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Radius Health multipliers

Report period2016 2017 2018 2019 2020 2021
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
Net Debt/EBITDA adj.
EV/EBITDA
EV/EBITDA adj.

Radius Health profitability

Report period2016 2017 2018 2019 2020 2021
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Radius Health assets
Radius Health cash flows

Radius Health dividend policy

The company doesn't provide dividend
Radius Health news
15.08.2022
Gurnet Point Capital and Patient Square Capital completed the acquisition of Radius Health for $890 million. Radius shareholders received $10 per share. Also, if abaloparatide reaches $300 million in TTM sales by December 31, 2025, shareholders will receive another $1 per share.
Source: {source} pictogram radiuspharm.com
Pictogram next
23.06.2022
Gurnet Point Capital and Patient Square Capital are buying biopharmaceutical company Radius Health for $890 million. Radius shareholders will receive $10 per share. Also, if abaloparatide reaches $300 million in TTM sales by December 31, 2025, shareholders will receive another $1 for each share. The transaction is expected to close in Q3 2022.
Source: {source} pictogram ir.radiuspharm.com
Pictogram next
05.05.2022
The loss of Radius Health under GAAP for 3 months of 2022 was $18.276 million, up 16% from $15.749 million in the previous year. Revenue decreased 23.3% to $43.158 million from $56.261 million a year earlier.
Source: {source} pictogram ir.radiuspharm.com
Pictogram next
24.02.2022
Radius Health's GAAP loss for 2021 was $70.176 million, down 35.7% from $109.208 million in the prior year. Revenue declined 3.6% to $229.973 million from $238.645 million a year earlier.
Source: {source} pictogram ir.radiuspharm.com
Pictogram next
All Radius Health news
General information
Company nameRadius Health
Tags#pharmacy
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals
Business address950 Winter Street Waltham, MA 02451 United States
Mailing address950 Winter Street Waltham, MA 02451 United States
Websiteir.radiuspharm.com
Information disclosurewww.sec.gov